List of Excipients in Branded Drug RYANODEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eagle Pharmaceuticals Inc	RYANODEX	dantrolene sodium	42367-540	HYDROCHLORIC ACID
Eagle Pharmaceuticals Inc	RYANODEX	dantrolene sodium	42367-540	MANNITOL
Eagle Pharmaceuticals Inc	RYANODEX	dantrolene sodium	42367-540	NITROGEN
Eagle Pharmaceuticals Inc	RYANODEX	dantrolene sodium	42367-540	POLYSORBATE 80
Eagle Pharmaceuticals Inc	RYANODEX	dantrolene sodium	42367-540	POVIDONE K12

RYANODEX Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 1, 2026

RYANODEX is a high-concentration dantrolene sodium injection developed to reduce the preparation burden associated with emergency treatment of malignant hyperthermia. Its commercial differentiation depends on formulation engineering, particularly the use of mannitol and polysorbate 80 to support a 250 mg dose that reconstitutes in 5 mL of sterile water. The product’s strongest opportunities are hospital emergency kits, operating-room preparedness, ambulatory surgery centers, and international markets where rapid malignant-hyperthermia response is required.

What is RYANODEX and how does its formulation differ from legacy dantrolene?

RYANODEX contains dantrolene sodium and is supplied as a 250 mg lyophilized powder in a single-dose vial. The product is reconstituted with 5 mL of sterile water for injection, producing a 50 mg/mL solution.[1]

Legacy intravenous dantrolene products, including Dantrium and Revonto, generally contain 20 mg per vial and require approximately 60 mL of sterile water for injection per vial. Treating a 70 kg adult at the initial recommended dose of 2.5 mg/kg may therefore require a large number of vials and substantial preparation volume.[2]

Product	Dantrolene per vial	Reconstitution volume	Approximate concentration after reconstitution	Primary operational issue
RYANODEX	250 mg	5 mL	50 mg/mL	Higher unit price and limited alternative suppliers
Dantrium IV	20 mg	60 mL	0.33 mg/mL	Large preparation volume
Revonto	20 mg	60 mL	0.33 mg/mL	Large preparation volume

RYANODEX’s excipient strategy is linked directly to its emergency-use value proposition. The formulation must permit rapid wetting, dissolution, physical stability, and delivery at a high drug concentration without requiring a large volume of diluent.

Which excipients are used in RYANODEX?

RYANODEX contains mannitol and polysorbate 80 as key formulation excipients. The product labeling identifies the 250 mg vial as containing 125 mg of mannitol and 5 mg of polysorbate 80 in addition to dantrolene sodium.[1]

Mannitol

Mannitol performs several formulation functions:

• It acts as a bulking agent in the lyophilized cake.
• It helps provide a physically robust freeze-dried structure.
• It supports rapid dissolution after sterile-water addition.
• It may contribute to tonicity and solids content.
• It can improve manufacturing consistency for a high-dose vial.

The mannitol-to-dantrolene ratio is approximately 0.5:1 by mass. That ratio is materially lower than the amount of mannitol historically associated with legacy dantrolene products, which required much larger reconstitution volumes.

Polysorbate 80

Polysorbate 80 is a nonionic surfactant. In RYANODEX, it likely supports wetting and dispersion of the dantrolene-containing cake after reconstitution. The excipient can reduce interfacial adsorption and help maintain solution uniformity during preparation.

Polysorbate 80 also introduces quality-control requirements. Relevant controls include peroxide content, degradation products, subvisible particles, container interaction, and lot-to-lot variability. These issues matter in an injectable product used in emergency settings because formulation performance must remain consistent after storage and rapid preparation.

Sodium hydroxide and pH control

Dantrolene sodium has limited aqueous solubility under some conditions. The product is formulated as an alkaline solution after reconstitution. The labeling instructs users to inspect the solution and discard unused material after preparation.[1] pH adjustment and control are therefore central to formulation performance, even where the commercial label does not identify every processing aid or pH-control component as a principal excipient.

How does RYANODEX’s excipient strategy create commercial value?

The commercial value does not arise from excipient novelty alone. It comes from the interaction between excipients, lyophilization, vial fill, reconstitution volume, and emergency workflow.

A typical malignant-hyperthermia response requires rapid delivery of dantrolene while clinicians manage airway, temperature, acidosis, hyperkalemia, and cardiac complications. RYANODEX reduces the number of vials and the amount of sterile water required for the initial dose.[1,3]

For a 70 kg patient receiving 2.5 mg/kg:

Metric	RYANODEX	20 mg legacy vial
Initial dantrolene dose	175 mg	175 mg
Vials required	1 vial, with residual product	9 vials
Reconstitution water	5 mL	Approximately 540 mL
Concentration	50 mg/mL	Approximately 0.33 mg/mL

The operational benefits include fewer manipulations, less vial handling, less water transfer, lower risk of preparation delay, and reduced staff burden. These benefits support premium pricing, hospital formulary preference, and use in facilities where malignant hyperthermia preparedness is required but emergency pharmacy resources are limited.

What formulation characteristics are protected by RYANODEX patents?

RYANODEX’s intellectual-property value is expected to center on formulation and dosage-form claims rather than on broad exclusivity for dantrolene itself. Dantrolene is an established active ingredient, so commercial protection depends on claim scope covering combinations of:

• High dantrolene concentration.
• Specific excipient ratios.
• Lyophilized or solid pharmaceutical compositions.
• Rapid reconstitution with a small volume of aqueous diluent.
• Stability during storage.
• Injectable administration for malignant hyperthermia.
• Manufacturing methods for producing the high-concentration cake.

The relevant patent analysis should separate three categories:

1. Composition claims covering dantrolene, mannitol, polysorbate 80, and related excipient ranges.
2. Method-of-use claims covering treatment or prevention of malignant hyperthermia.
3. Manufacturing claims covering lyophilization, filling, drying, and reconstitution performance.

A generic developer could challenge the estate by arguing that the formulation is obvious from conventional lyophilized injectable technology, that excipient ranges lack unexpected results, or that method-of-use claims are limited by prior art and label scope. The branded company’s strongest position would come from comparative evidence showing materially faster reconstitution, improved stability, or clinically relevant preparation advantages over 20 mg dantrolene products.

What is the FDA regulatory status of RYANODEX?

The FDA approved RYANODEX in July 2014 for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures.[4] It is an injectable drug-device workflow product rather than a biologic, so biosimilar competition is not applicable.

The product is regulated through the abbreviated new drug application pathway for potential generic competitors if a developer can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable requirements. The high-concentration formulation creates a more difficult development program than a conventional 20 mg dantrolene vial because the applicant must address:

• Drug-product sameness.
• Reconstitution time.
• Appearance and particulate matter.
• Assay and degradation products.
• Container-closure integrity.
• Stability of the lyophilized cake.
• Compatibility with sterile water for injection.
• Labeling and emergency-use instructions.

When does RYANODEX lose exclusivity?

RYANODEX’s active ingredient is off-patent, but product-level exclusivity depends on listed patents, regulatory exclusivity, and any litigation or settlement agreements. The FDA Orange Book should be reviewed for current patent listings and pediatric-exclusivity adjustments.[5]

The commercial entry risk is likely to develop in stages:

Period	Competitive risk
Before listed-patent expiry	Paragraph IV certification, patent litigation, and possible at-risk launch
Near patent expiry	ANDA filings, settlement negotiations, and hospital purchasing trials
After patent expiry	Generic high-concentration dantrolene risk
Long term	Price erosion and possible differentiation by vial size, stability, or global supply

Because malignant hyperthermia is a low-frequency, high-severity emergency, substitution may occur more slowly than in high-volume chronic medicines. Hospitals may retain the branded product if clinicians value preparation speed and supply reliability. Generic competition could still reduce price if the substitute matches reconstitution time and clinical workflow.

What Paragraph IV challenges could affect RYANODEX?

A Paragraph IV challenger could target formulation patents by asserting that the claims are invalid, not infringed, or not eligible for listing against the approved product. The most credible attack vectors would involve:

• Obviousness based on known dantrolene formulations.
• Lack of written description for broad excipient ranges.
• Lack of enablement for wide concentration or stability claims.
• Non-infringement through altered surfactant levels or alternative bulking agents.
• Use of a different lyophilization process.
• A product that requires a slightly different reconstitution procedure.

The branded company could respond with formulation-development data, accelerated and long-term stability results, reconstitution testing, and evidence that the excipient combination solves a recognized emergency-use problem.

The key competitive question is not whether a generic can contain dantrolene. It is whether the generic can reproduce the commercial performance of RYANODEX without infringing formulation or manufacturing claims.

What commercial opportunities exist for RYANODEX excipient technology?

Hospital emergency preparedness

Hospitals and ambulatory surgery centers represent the core market. Purchasing decisions are influenced by operating-room protocols, malignant-hyperthermia cart design, pharmacy staffing, and anesthesia department preferences.

A supplier could expand commercial value through:

• Emergency-cart packaging.
• Ready-to-use preparation kits.
• Inventory rotation programs.
• Bundled sterile-water supply.
• Barcode and medication-management integration.
• Training materials for rapid reconstitution.

International expansion

The formulation may have value in countries where legacy dantrolene preparation imposes high labor or water-volume requirements. International opportunities depend on local approval, pricing, malignant-hyperthermia protocols, and procurement systems.

Geographic expansion is more attractive where:

• Operating rooms are geographically dispersed.
• Pharmacy compounding support is limited.
• Surgical volumes are high.
• National guidelines require dantrolene availability.
• Hospitals pay for emergency-readiness products.

Alternative vial sizes

A 250 mg vial is efficient for adult rescue dosing but can create residual waste in smaller patients. Potential line extensions include:

• A 100 mg or 125 mg vial.
• A pediatric-oriented presentation.
• Dual-pack emergency kits.
• A premixed or ready-to-use liquid, if stability permits.
• A higher-margin presentation for ambulatory surgery centers.

A smaller vial could reduce waste but would increase manufacturing, packaging, and inventory complexity. The commercial case depends on whether waste reduction outweighs the loss of the 250 mg vial’s preparation advantage.

Excipient-led follow-on products

The underlying formulation approach could support products using:

• Alternative surfactants with lower peroxide risk.
• Novel bulking agents.
• Trehalose or sucrose for improved cake structure.
• Amino-acid stabilizers.
• Improved container-closure systems.
• Ready-to-dilute liquid presentations.

Any reformulation would need to preserve the product’s central performance metric: fast and reliable preparation during a time-critical emergency.

How strong is the RYANODEX patent estate?

The estate is commercially meaningful if it claims the specific combination of high concentration, excipient composition, lyophilized structure, and rapid reconstitution. Broad claims covering dantrolene and conventional excipients would face greater invalidity risk because the active ingredient and many injectable excipients are old.

Patent strength is highest when claims are supported by:

• Narrow, clearly defined excipient ratios.
• Comparative reconstitution data.
• Unexpected stability at high concentration.
• Reduced preparation time relative to legacy products.
• Reproducible manufacturing parameters.
• Claims tied to the approved 250 mg/5 mL presentation.

Patent strength is weaker if protection depends only on routine selection of mannitol, polysorbate 80, and lyophilization without evidence of an unexpected technical effect.

What litigation and settlement issues affect RYANODEX?

Potential litigation would likely involve an ANDA filer asserting Paragraph IV positions against listed formulation or method-of-use patents. The business impact would depend on the filing date, patent-term-adjustment periods, pediatric exclusivity, settlement terms, and whether the challenger receives a licensed launch date.

Settlement analysis should focus on:

• Whether the generic receives an authorized launch date.
• Whether the agreement includes supply or licensing rights.
• Whether the challenger can launch with a non-infringing formulation.
• Whether the settlement includes volume restrictions or market allocation provisions.
• Whether the Federal Trade Commission reviews the arrangement.

No biosimilar litigation pathway applies because dantrolene sodium is a small-molecule active ingredient.

How does RYANODEX compare with other dantrolene products?

RYANODEX has the clearest product differentiation in preparation efficiency. Dantrium and Revonto have the advantage of established use and potentially broader supplier familiarity, but their low concentration creates a substantial reconstitution burden.

Factor	RYANODEX	Dantrium/Revonto
Active ingredient	Dantrolene sodium	Dantrolene sodium
Vial strength	250 mg	20 mg
Reconstitution burden	Low	High
Emergency workflow differentiation	Strong	Limited
Generic substitution risk	Formulation-dependent	Established conventional formulation
Excipient opportunity	High-concentration lyophilized system	Incremental improvement
Biosimilar risk	None	None

Key Takeaways

• RYANODEX uses dantrolene sodium, mannitol, and polysorbate 80 in a 250 mg lyophilized vial.
• Its commercial advantage is the 5 mL reconstitution volume versus approximately 60 mL for 20 mg legacy vials.
• The strongest intellectual-property claims are likely to involve high concentration, excipient ratios, lyophilization, rapid reconstitution, and manufacturing controls.
• Generic risk is driven by the ability to match preparation performance, not simply by reproducing dantrolene sodium.
• Biosimilar competition does not apply.
• The most credible commercial opportunities are hospital emergency kits, ambulatory surgery centers, international expansion, smaller vial sizes, and improved ready-to-use presentations.
• Formulation patents are strongest when supported by comparative data showing unexpected stability or materially faster reconstitution.

FAQs

Can RYANODEX be reformulated without polysorbate 80?

A competing product could use another surfactant, but it would need to demonstrate acceptable wetting, dissolution, stability, particulate control, and injectable safety. A substitute surfactant could also provide a design-around strategy against claims limited to polysorbate 80.

Is mannitol essential to RYANODEX performance?

Mannitol is important to the lyophilized cake and formulation solids profile, but it is not necessarily irreplaceable. Trehalose, sucrose, glycine, or other bulking and stabilizing systems could be evaluated, subject to reconstitution and stability requirements.

Could a generic RYANODEX use the same excipients at different concentrations?

Potentially. A generic applicant could seek to avoid specific formulation claims by changing excipient ratios, provided the resulting product meets FDA requirements for pharmaceutical equivalence, quality, stability, and labeling.

Does RYANODEX have patent protection for malignant-hyperthermia treatment itself?

Method-of-use protection may exist, but the active ingredient’s long clinical history limits the strength of broad treatment claims. Product and formulation claims are generally more important to commercial exclusivity.

What is the main manufacturing barrier for a RYANODEX competitor?

The main barrier is reproducible manufacture of a high-dose lyophilized injectable that rapidly reconstitutes in 5 mL while meeting sterility, particulate, stability, container-closure, and potency requirements.

References

1. U.S. Food and Drug Administration. (2023). RYANODEX (dantrolene sodium) for injectable suspension: Prescribing information. Eagle Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2023). Dantrium intravenous and Revonto prescribing information. FDA Drugs@FDA.

3. Association of Anaesthetists. (2021). Management of a malignant hyperthermia crisis: Guidelines. Anaesthesia, 76(5), 655-664.

4. U.S. Food and Drug Administration. (2014). FDA approves RYANODEX for treatment of malignant hyperthermia. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.